Mounjaro and Thyroid: What People on Tirzepatide Should Know

During pre-clinical studies of GLP-1 receptor agonists — the drug class that includes both tirzepatide (Mounjaro) and semaglutide (Wegovy) — thyroid C-cell tumours were observed in rodents. This finding led to a precautionary contraindication: people with a personal or family history of medullary thyroid carcinoma (MTC), or those with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), are generally not considered suitable candidates for these medicines.

Importantly, rodent thyroid C-cells respond differently to GLP-1 receptor stimulation than human thyroid cells do. According to product information published on the electronic Medicines Compendium, the clinical relevance of the rodent findings to humans has not been established. Long-term post-marketing surveillance continues, as is standard for newer medicines that carry additional monitoring requirements.

Regarding the question many people ask — whether anyone has developed thyroid cancer from Wegovy or Mounjaro — no confirmed causal cases in humans have been established based on current evidence. However, these medicines are relatively recent, and ongoing monitoring remains important. Any new or unusual neck symptoms (such as a lump, hoarseness, or difficulty swallowing) should be discussed with a healthcare professional promptly, rather than attributed to the medication without assessment.

For a deeper look at how these medicines interact with thyroid function more broadly, see our page on Mounjaro and thyroid function, and if you have an underactive thyroid and are wondering how that affects your journey, our guide on Mounjaro and underactive thyroid covers what to be aware of. You can also read about other research areas in our Mounjaro and cancer research overview.

If you have thyroid-related concerns while taking Mounjaro, the most useful thing you can do — beyond speaking with your prescriber — is keep a clear record of any symptoms you notice over time. This is where GLP Trackr's side-effect and symptom tracking becomes genuinely practical: you can log symptoms such as neck discomfort, fatigue, or unexpected weight changes as they occur, with dates and notes, so you have an accurate picture to bring to your next appointment rather than relying on memory.

The app also includes a doctor report feature that compiles your logged data — weight trends, energy levels, side effects, and dose history — into a clear summary. When thyroid function and weight loss interact in complex ways, having that documented timeline can make conversations with your healthcare team much more productive.

Any concerns about your thyroid — whether a new symptom, a question about your history, or uncertainty about whether tirzepatide is still appropriate for you — should be directed to your prescriber or doctor. GLP Trackr is a tracking and journaling tool; it is not a substitute for clinical assessment, and it cannot evaluate whether a symptom is significant. If you experience any new neck symptoms, changes to your voice, or lumps in your neck, contact a healthcare professional without delay.

If you are on a national post-market surveillance programme, any suspected side effects — including thyroid-related concerns — should be reported through your national reporting scheme (such as the UK Yellow Card scheme) as well as to your healthcare professional.

For a broader overview of Mounjaro, its uses, and what to expect on your journey, visit our Mounjaro information hub.

Start logging your symptoms and building a record you can share with your prescriber — GLP Trackr is free to try for 7 days, available on the App Store and Google Play.